Ozempic contains semaglutide, a GLP-1 receptor agonist. Its effects on appetite have prompted research into cognition and addiction. The useful question is what happened to people in controlled trials, rather than whether a scan or laboratory experiment suggests an interesting mechanism.

Evidence update, September 10, 2026: This article replaces its earlier statement that EVOKE results were pending and removes unsupported claims about oral medicines reaching brain regions that injections cannot.

How does GLP-1 affect appetite?

GLP-1 is a hormone involved in the body's response to food. It influences insulin and glucagon release, gastric emptying and food intake. GLP-1 receptor medicines act on this signaling system; their action is not confined to the stomach.1 That physiology does not mean every formulation has identical brain exposure or that a change in appetite proves an effect on memory.

Did semaglutide slow Alzheimer disease?

No significant benefit was demonstrated in EVOKE or EVOKE+. The two phase 3 trials enrolled 3,808 people with early symptomatic Alzheimer disease and compared oral semaglutide with placebo. The main clinical measure tracked cognitive and functional deterioration. The results did not establish slower progression with semaglutide.2

Earlier observational associations and laboratory findings helped motivate these trials. They cannot override a negative randomized result. This finding concerns treatment of established early symptomatic Alzheimer disease; it does not answer every possible prevention question or negate a medicine's benefits for a different indication.

What do the alcohol-use trials show?

A 2025 randomized trial of weekly semaglutide reported reductions in some drinking and craving outcomes.3 A separate 2026 trial of oral semaglutide enrolled 50 adults with moderate to severe alcohol use disorder. It did not significantly improve its primary laboratory craving outcome or drinks per day, although heavy drinking days and some other measures improved.4

These are reasons for further study, with attention to the population, formulation, duration and outcome selected. They are not a basis for assuming that semaglutide treats nicotine dependence, shopping behavior or all addictions.

What about mood changes?

Individual symptoms deserve assessment, but reports alone cannot show that a drug caused them. In January 2026, the FDA said its review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of that warning from affected labels.5 This does not mean every mood symptom has been explained. Discuss persistent mood or motivation changes with the prescribing clinician.

How should patients read a brain-health headline?

  1. Check the population: people with diabetes, healthy volunteers and people with Alzheimer disease answer different questions.
  2. Check the outcome: a biomarker or brain scan is not the same as better memory or daily function.
  3. Check the study: an observational association can suggest a trial; randomized results test whether treatment helps.

Bring the actual study to a medication discussion. For the vascular side of cognition, continue with stroke and dementia and vascular health and brain function.